Bolt Biotherapeutics Appoints Willie Quinn as Chief Executive Officer

Redwood City, CA, May 14, 2024 (Globe Newswire) -- Bolt Biotherapeutics, a biopharmaceutical firm headquartered in Redwood City, California, unveiled its financial performance for the first quarter of 2024 while concurrently announcing a strategic realignment and leadership reshuffle. Emphasizing a shift in focus, the company delineated its intent to prioritize its pioneering agonist antibody targeting Dectin-2 and its cutting-edge Boltbody™ ISAC programs, alongside continued support for partnerships with Genmab and Toray. This strategic pivot also includes the appointment of Willie Quinn as Chief Executive Office.

Read full article here.